Sarepta Therapeutics Inc. announced the advancement of its siRNA collaboration, specifically highlighting progress in the Phase 1/2 clinical study of SRP-1003, an investigational RNA interference therapeutic aimed at treating type 1 myotonic dystrophy $(DM1.AU)$. The company reported that a $100 million milestone payment obligation was triggered after achieving a predetermined enrollment target in the study. Sarepta plans to release preliminary data from this study in the second half of 2025. Additionally, Sarepta has sold a portion of its common stock holdings in Arrowhead Pharmaceuticals, Inc. to generate at least $174 million in gross proceeds and has made arrangements to transfer shares to Arrowhead to fulfill part of the milestone payment. The company emphasizes that these financial moves are strategic and do not reflect a change in their belief in the potential of siRNA technology.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。